Walleye Trading’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-32,724
Closed -$224K 5023
2023
Q3
$224K Sell
32,724
-13,603
-29% -$116K ﹤0.01% 3534
2023
Q2
$480K Buy
+46,327
New +$419K ﹤0.01% 2775
2023
Q1
Sell
-22,009
Closed -$347K 4782
2022
Q4
$347K Buy
22,009
+983
+5% +$15.8K ﹤0.01% 3144
2022
Q3
$331K Buy
+21,026
New +$331K ﹤0.01% 3298
2019
Q3
Sell
-55,000
Closed -$120K 3959
2019
Q2
$120K Buy
+55,000
New +$300K ﹤0.01% 3229

Other funds holding ACRS

Walleye Trading's ACRS Position: Q4 2023 in Review

Walleye Trading sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 32,724 shares — an estimated $224K sold.

Walleye Trading first reported a position in ACRS in Q2 2019 and held it in 5 quarters. The position peaked at $480K in Q2 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • Walleye Trading reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Walleye Trading sold 32,724 Aclaris Therapeutics shares in Q4 2023, an estimated $224K.
  • Walleye Trading first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 5 quarters.
  • Walleye Trading's Aclaris Therapeutics position peaked at $480K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Walleye Trading's 13F filing for Q4 2023, filed 14 Feb 2024.